Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Untreated HIV infection is associated with higher blood alcohol levels.

McCance-Katz EF, Lum PJ, Beatty G, Gruber VA, Peters M, Rainey PM.

J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):282-8. doi: 10.1097/QAI.0b013e318256625f.

2.

Interactions between alcohol and the antiretroviral medications ritonavir or efavirenz.

McCance-Katz EF, Gruber VA, Beatty G, Lum PJ, Rainey PM.

J Addict Med. 2013 Jul-Aug;7(4):264-70. doi: 10.1097/ADM.0b013e318293655a.

3.

Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.

PMID:
24852077
4.

Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.

Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD004772. doi: 10.1002/14651858.CD004772.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;(5):CD004772.

PMID:
22786492
5.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
6.
7.

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.

Neukam K, Mira JA, Ruiz-Morales J, Rivero A, Collado A, Torres-Cornejo A, Merino D, de Los Santos-Gil I, Macías J, González-Serrano M, Camacho A, Parra-García G, Pineda JA; SEGURIDAD HEPÁTICA Study Team of the Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)..

J Antimicrob Chemother. 2011 Nov;66(11):2605-14. doi: 10.1093/jac/dkr357.

PMID:
21903660
8.

Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women.

Natureeba P, Ades V, Luwedde F, Mwesigwa J, Plenty A, Okong P, Charlebois ED, Clark TD, Nzarubara B, Havlir DV, Achan J, Kamya MR, Cohan D, Dorsey G.

J Infect Dis. 2014 Dec 15;210(12):1938-45. doi: 10.1093/infdis/jiu346.

9.

Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial.

Kasang C, Kalluvya S, Majinge C, Kongola G, Mlewa M, Massawe I, Kabyemera R, Magambo K, Ulmer A, Klinker H, Gschmack E, Horn A, Koutsilieri E, Preiser W, Hofmann D, Hain J, Müller A, Dölken L, Weissbrich B, Rethwilm A, Stich A, Scheller C.

PLoS One. 2016 Jan 26;11(1):e0146678. doi: 10.1371/journal.pone.0146678.

10.

Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.

Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT.

AIDS. 2006 May 12;20(8):1171-9.

PMID:
16691069
11.

Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.

Sturt AS, Dokubo EK, Sint TT.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008440. doi: 10.1002/14651858.CD008440. Review.

PMID:
20238370
12.

Alcohol use accelerates HIV disease progression.

Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A.

AIDS Res Hum Retroviruses. 2010 May;26(5):511-8. doi: 10.1089/aid.2009.0211.

13.

Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.

Cohan D, Natureeba P, Koss CA, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Gandhi M, Clark TD, Nzarubara B, Achan J, Ruel T, Kamya MR, Havlir DV.

AIDS. 2015 Jan 14;29(2):183-91. doi: 10.1097/QAD.0000000000000531.

14.

Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM.

AIDS. 2000 Jun 16;14(9):F103-10.

PMID:
10894270
15.

Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries.

Hirsch JD, Rosenquist A, Best BM, Miller TA, Gilmer TP.

J Manag Care Pharm. 2009 Jan-Feb;15(1):32-41.

16.

Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.

Hattab S, Guihot A, Guiguet M, Fourati S, Carcelain G, Caby F, Marcelin AG, Autran B, Costagliola D, Katlama C.

BMC Infect Dis. 2014 Mar 4;14:122. doi: 10.1186/1471-2334-14-122.

17.

A randomized controlled trial to enhance antiretroviral therapy adherence in patients with a history of alcohol problems.

Samet JH, Horton NJ, Meli S, Dukes K, Tripps T, Sullivan L, Freedberg KA.

Antivir Ther. 2005;10(1):83-93.

PMID:
15751766
18.

Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.

Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005481. doi: 10.1002/14651858.CD005481.pub3. Review.

PMID:
23543540
19.

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Xu X, Sklar P; SWITCHMRK 1 and 2 investigators..

Lancet. 2010 Jan 30;375(9712):396-407. doi: 10.1016/S0140-6736(09)62041-9.

PMID:
20074791
20.

Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.

Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR; AIDS Clinical Trials Group A5248 Team..

J Infect Dis. 2013 Sep;208(6):884-91. doi: 10.1093/infdis/jit272.

Supplemental Content

Support Center